Trial Profile
Monotherapy with Ofatumumab for RElapsed/refractory Splenic B-cell marginal zone lymphoma (MORE)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- Acronyms MORE
- 04 Dec 2018 Interim results (n=15;data cut off 11 July 2018) evaluating the activity and safety of ofatumumab mono therapy in patients with splenic marginal-zone lymphoma presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 25 Jun 2017 Results of safety analysis (n=10), presented at the 22nd Congress of the European Haematology Association.
- 01 Apr 2015 New trial record